Leaflet SYNAGIS 100mg / ml solution for injection
Indicated for: prevention of respiratory syncytial virus disease
Route of administration: injectable
Substance: palivizumab (monoclonal antibody)
ATC: J06BB16 (Antiinfectives for systemic use | Immunoglobulins | Specific immunoglobulins)
Palivizumab is a monoclonal antibody used for the prevention of severe respiratory syncytial virus (RSV) infections in infants and children at high risk. It works by binding to the F protein of the virus, preventing its replication.
The medication is administered via intramuscular injection, usually once a month during the RSV season, as directed by your doctor. It is important to follow the administration schedule to ensure optimal protection.
Side effects may include injection site reactions, fever, rash, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any known allergies or other conditions to ensure the safe use of palivizumab.
General data about SYNAGIS 100mg / ml
- Substance: palivizumab
- Date of last drug list: 01-06-2021
- Commercial code: W67585001
- Concentration: 100mg / ml
- Pharmaceutical form: solution for injection
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for palivizumab
Concentrations available for palivizumab
- 100mg
- 100mg/ml
- 50mg
